BOSTON & LONDON -- (BUSINESS WIRE) -- Today at Disruptive Innovations 2013 in Boston, TrialReach - the website that connects patients to clinical trials worldwide - is launching a new platform that dramatically reduces the time and costs required to find clinical trial participants.
http://trialreach.com (Photo: Business Wire)
One of the biggest challenges in clinical research is finding patients. It is estimated that 80% of all trials miss their deadlines, causing losses of up to $8M per drug per day and slowing up the process of getting new treatments to patients.
TrialReach’s new platform offers an efficient, unique, highly scalable, and much needed solution to this problem. To make the process super simple for patients, complicated medical research protocols are converted into simple, patient-friendly interactive multimedia web pages on the go. Vitally, patients will have the opportunity to find out immediately if they are eligible for a trial through easy-to-use pre-screeners.
For medical researchers, they are now able to reach millions of patients in just a few clicks. Unlike other initiatives, the TrialReach platform is open and virtually free to all research teams, even to smaller biotech firms and academic institutions. The significance of lowering the barrier of entry for all researchers will transform the entire sector, as many more treatments in development will be exposed to patients in a useful and reliable manner. The platform will have immediate industry wide-impact.
“TrialReach is helping us to solve one of the biggest challenges in medical research - making it much easier for patients to find us, learn more and then volunteer to be in our clinical trials.” says Professor Steve Williams, Head of Dept, King’s College London.
“The new TrialReach platform is a win-win for patients and clinical researchers,” says TrialReach CEO, Pablo Graiver. “Our goal is to democratize the information and access to medical research, so it can transform the whole industry and not just selected companies. TrialReach may be the only way for independent teams to find patients for their trials. We want patients to have access to all clinical trials because we don’t know which team will come up with the most effective treatment for any given condition.”